Jason Baron, M.D. of Med Labs Research leads analysis for bounded patients
Houston, TX, February 10, 2009: Imagine traveling through the day after the adeptness to apply and focus on the things you adore and important tasks that you charge to complete. Think what it would be like, disturbing to bethink what you just talked about or abstruse a abbreviate time ago. Consider how you would feel if you couldn't even accomplish simple tasks, such as authoritative a buzz call, grocery arcade or scheduling an appointment.
We all accept arduous moments . . . but for humans adversity from schizophrenia, these frustrations are a way of life, around every day. People with schizophrenia attempt to concentrate, bethink and learn. These deficits associated with the cerebration action are alleged cerebral impairments, authoritative it difficult to accomplish the demands of accustomed life, both big and small.
Managing the demands of circadian activity is fabricated easier if individuals with schizophrenia advance a abiding dieting of medication - even added so for those with trusted family associates or caregivers to advice baby-sit the individual's claimed address and alike care. Despite the challenges, a lot of humans with schizophrenia and their caregivers are analytic for a bigger above of life.
Fortunately, there is hope, acknowledgment to a new investigational drug analysis study now underway in the Houston, TX area. The primary ambition of this abstraction is to appraise the assurance and capability of an investigational biologic in convalescent cerebral activity for humans with schizophrenia, application a new appraisal apparatus alleged MATRICS (Measurement and Treatment Research to Improve Cognition in Schizophrenia). This abstraction is different because participants are not appropriate to change their already-stable medication regimen. Rather, the new investigational medication is added to their currently accustomed treatment.
Candidates for this abstraction have to be 18 to 65 years old, diagnosed with schizophrenia at or afore age 35 and currently demography one of 5 medications for schizophrenia which cover olanzapine, risperidone/paliperidone, quetiapine or aripiprazole. Participants have to aswell be advised outpatient (living in the community). Qualified abstraction participants will accept all investigational medication and study-related affliction at no cost, and may aswell accept advantage for travel.
Jason Baron, M.D. of Med Labs Research seeks participants for this new study. If you or anyone you apperceive suffers from schizophrenia, amuse contact us for added advice at 888.988.6736. Further data about the abstraction are aswell accessible at http://www.cognitivestudy.com.
Contact:
Hal Coxon
Axiom Accelerated Clinical Patient Recruitment
(847) 919-1005
halcoxon (at) axmarketing.com
###
Post Comment:
Trackback URL: http://www.prweb.com/pingpr.php/WmV0YS1QaWdnLUVtcHQtU2luZy1DcmFzLVNpbmctWmVybw==
Bookmark - Del.icio.us | Furl It | Technorati | Ask | MyWeb | Propeller | Live Bookmarks | Newsvine | TailRank | Reddit | Slashdot | Digg | Stumbleupon | Google Bookmarks | Sphere | Blink It | Spurl
No comments:
Post a Comment